Glycerophosphoglycerol, Beta-Alanine, and Pantothenic Acid as Metabolic Companions of Glycolytic Activity and Cell Migration in Breast Cancer Cell Lines

Metabolites

Antje Hutschenreuther¹  Gerd Birkenmeier¹  Marina Bigl¹  Knut Krohn² 

[1] Medical Faculty, Institute of Biochemistry, University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany; E-mails:;University of Leipzig, IZKF Core Unit DNA-Technologies, Liebigstr 21, 04103 Leipzig, Germany; E-mail:

关键词: breast cancer;    metabolite profiling;    LDH;    Glo1;    glycolysis;    Warburg hypothesis;    cell migration;   

DOI  :  10.3390/metabo3041084

来源: mdpi

【 摘 要 】

In cancer research, cell lines are used to explore the molecular basis of the disease as a substitute to tissue biopsies. Breast cancer in particular is a very heterogeneous type of cancer, and different subgroups of cell lines have been established according to their genomic profiles and tumor characteristics. We applied GCMS metabolite profiling to five selected breast cancer cell lines and found this heterogeneity reflected on the metabolite level as well. Metabolite profiles of MCF-7 cells belonging to the luminal gene cluster proved to be more different from those of the basal A cell line JIMT-1 and the basal B cell lines MDA-MB-231, MDA-MB-435, and MDA-MB-436 with only slight differences in the intracellular metabolite pattern. Lactate release into the cultivation medium as an indicator of glycolytic activity was correlated to the metabolite profiles and physiological characteristics of each cell line. In conclusion, pantothenic acid, beta-alanine and glycerophosphoglycerol appeared to be related to the glycolytic activity designated through high lactate release. Other physiological parameters coinciding with glycolytic activity were high glyoxalase 1 (Glo1) and lactate dehydrogenase (LDH) enzyme activity as well as cell migration as an additional important characteristic contributing to the aggressiveness of tumor cells. Metabolite profiles of the cell lines are comparatively discussed with respect to known biomarkers of cancer progression.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.